Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

<p>Regina Hodits, who I have known for many years, spent 15 years at Wellington Partners before joining Angelini Ventures in 2025. The corporate venture fund now manages close to €500M, and its first exit, Noctrix Health, sold to ResMed for $340M in June.We talked about Forbion, Jeito and Sofinnova’s mega-funds, why Europe still needs more institutional money for biotech, and why “spray and pray” doesn’t work at the Series A and B levels of investing.We also covered the “red hot” rare-disease segment, and why her biotech hero is Nobel laureate Sir Gregory Winter.</p><p>---This episode is brought to you by Avance Life Sciences, where European biotech turns for trusted financial advice. Learn more <a target="_blank" rel="ugc noopener noreferrer">at https://bit.ly/flot-avance</a>---</p><p>⭐️ ABOUT THE SPEAKER</p><p>Since starting her Managing Director role at Angelini Ventures in 2025, Regina has served on the boards of companies including Adcytherix and Nuclidium. She was previously Managing Partner at Wellington Partners, where she managed 25+ investments, including Themis and Rigontec, both acquired by MSD.She was also a founding investor in Bicycle Therapeutics and F-star, and earlier worked at Atlas Venture, Apax and McKinsey. </p><p>🔗 LINKS MENTIONED</p><ul><li>Regina Hodits LinkedIn profile — <a href="https://www.linkedin.com/in/regina-hodits-270a7481/" target="_blank" rel="ugc noopener noreferrer">https://www.linkedin.com/in/regina-hodits-270a7481/</a></li><li>Angelini Ventures — <a href="https://www.angeliniventures.com/" rel="ugc noopener noreferrer" target="_blank">angeliniventures.com</a></li><li>EIB and Angelini Ventures, €150M agreement — <a href="https://www.eib.org/en/press/all/2025-485-eur150-million-agreement-between-eib-and-angelini-ventures-to-finance-european-startups" rel="ugc noopener noreferrer" target="_blank">eib.org</a></li><li>Angelini Ventures invests in Epicrispr's $90M Series C — <a href="https://www.angeliniventures.com/insights-and-news/epicrispr-investment/" rel="ugc noopener noreferrer" target="_blank">angeliniventures.com</a></li><li>ResMed acquires Noctrix Health, $340M — <a href="https://www.fiercebiotech.com/medtech/resmed-snaps-noctrix-health-340m-sleep-tech-deal" rel="ugc noopener noreferrer" target="_blank">fiercebiotech.com</a></li><li>RougeTx launches with $58M Series A — <a href="https://rougetx.com/rougetx-launches-with-58-million-series-a-financing-to-advance-first-in-class-treatment-for-hereditary-hemorrhagic-t